|
gptkbp:instanceOf
|
antiviral drug
|
|
gptkbp:administeredBy
|
gptkb:adefovir_dipivoxil
|
|
gptkbp:approvalYear
|
2002
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
J05AF08
|
|
gptkbp:bioavailability
|
59%
|
|
gptkbp:brand
|
gptkb:Hepsera
|
|
gptkbp:CASNumber
|
142340-99-6
|
|
gptkbp:chemicalFormula
|
C8H12N5O4P
|
|
gptkbp:contraindication
|
severe renal impairment
|
|
gptkbp:developedBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:drugClass
|
antiviral
nucleotide analogue
|
|
gptkbp:eliminationHalfLife
|
5-7 hours
|
|
gptkbp:excretion
|
renal
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
adefovir
|
|
gptkbp:IUPACName
|
(RS)-9-[2-(phosphonomethoxy)ethyl]adenine
|
|
gptkbp:KEGGID
|
D02807
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
nucleotide analogue reverse transcriptase inhibitor
|
|
gptkbp:MeSH_ID
|
D000068715
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:molecularWeight
|
273.18 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
less than 4%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
41856
45943
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
abdominal pain
headache
nephrotoxicity
lactic acidosis
asthenia
|
|
gptkbp:synonym
|
gptkb:9-(2-phosphonylmethoxyethyl)adenine
gptkb:bis(POM)_PMEA
|
|
gptkbp:UNII
|
91XWA6TQSB
|
|
gptkbp:usedFor
|
treatment of hepatitis B
|
|
gptkbp:bfsParent
|
gptkb:Hepatitis_B
|
|
gptkbp:bfsLayer
|
5
|